Literature DB >> 19365058

Highly selective leptomeningeal amyloidosis with transthyretin variant Ala25Thr.

K Hagiwara1, H Ochi, S Suzuki, Y Shimizu, T Tokuda, H Murai, H Shigeto, Y Ohyagi, M Iwata, T Iwaki, J-I Kira.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19365058     DOI： 10.1212/WNL.0b013e3181a0fe74

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  10 in total

Review 1.  Current and future treatment of amyloid diseases.

Authors:  M Ankarcrona; B Winblad; C Monteiro; C Fearns; E T Powers; J Johansson; G T Westermark; J Presto; B-G Ericzon; J W Kelly
Journal:  J Intern Med       Date:  2016-05-10       Impact factor: 8.989

2.  Age-dependent cognitive dysfunction in untreated hereditary transthyretin amyloidosis.

Authors:  Ana Martins da Silva; Sara Cavaco; Joana Fernandes; Raquel Samões; Cristina Alves; Márcio Cardoso; Jeffery W Kelly; Cecília Monteiro; Teresa Coelho
Journal:  J Neurol       Date:  2017-12-05       Impact factor: 4.849

3.  The identification of a transthyretin variant p.D38G in a Chinese family with early-onset leptomeningeal amyloidosis.

Authors:  Kuan Fan; Haixia Zhu; Hongbo Xu; Ping Mao; Lamei Yuan; Hao Deng
Journal:  J Neurol       Date:  2018-11-23       Impact factor: 4.849

4.  Activated microglia mediate synapse loss and short-term memory deficits in a mouse model of transthyretin-related oculoleptomeningeal amyloidosis.

Authors:  E P Azevedo; J H Ledo; G Barbosa; M Sobrinho; L Diniz; A C C Fonseca; F Gomes; L Romão; F R S Lima; F L Palhano; S T Ferreira; D Foguel
Journal:  Cell Death Dis       Date:  2013-09-05       Impact factor: 8.469

Review 5.  The Amyloid-Tau-Neuroinflammation Axis in the Context of Cerebral Amyloid Angiopathy.

Authors:  Pablo Cisternas; Xavier Taylor; Cristian A Lasagna-Reeves
Journal:  Int J Mol Sci       Date:  2019-12-14       Impact factor: 5.923

Review 6.  Current Review of Leptomeningeal Amyloidosis Associated With Transthyretin Mutations.

Authors:  Qi Qin; Cuibai Wei; YueShan Piao; Fang Lian; Hao Wu; Aihong Zhou; Fen Wang; Xiumei Zuo; Yue Han; Jihui Lyu; Dongmei Guo; Jianping Jia
Journal:  Neurologist       Date:  2021-09-07       Impact factor: 1.398

7.  Neuropathologic analysis of Tyr69His TTR variant meningovascular amyloidosis with dementia.

Authors:  Jennifer L Ziskin; Michael D Greicius; Wan Zhu; Anna N Okumu; Christopher M Adams; Edward D Plowey
Journal:  Acta Neuropathol Commun       Date:  2015-07-10       Impact factor: 7.801

8.  Oculoleptomeningeal Amyloidosis associated with transthyretin Leu12Pro in an African patient.

Authors:  P McColgan; S Viegas; S Gandhi; K Bull; R Tudor; F Sheikh; J Pinney; M Fontana; D Rowczenio; J D Gillmore; J A Gilbertson; C J Whelan; S Shah; Z Jaunmuktane; J L Holton; J M Schott; D J Werring; P N Hawkins; M M Reilly
Journal:  J Neurol       Date:  2014-12-09       Impact factor: 4.849

Review 9.  Diagnosis and Treatment of Hereditary Transthyretin Amyloidosis (hATTR) Polyneuropathy: Current Perspectives on Improving Patient Care.

Authors:  Marco Luigetti; Angela Romano; Andrea Di Paolantonio; Giulia Bisogni; Mario Sabatelli
Journal:  Ther Clin Risk Manag       Date:  2020-02-21       Impact factor: 2.423

10.  The Transthyretin/Oleuropein Aglycone Complex: A New Tool against TTR Amyloidosis.

Authors:  Francesco Bemporad; Manuela Leri; Matteo Ramazzotti; Massimo Stefani; Monica Bucciantini
Journal:  Pharmaceuticals (Basel)       Date:  2022-02-23
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.